

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Yechiel Shai et al.

Confirmation No.: 8544

Application No.: 10/560,727

Patent No.: 7,671,011 B2

Filing Date: October 10, 2006

Patent Date: March 2, 2010

For: ANTIMICROBIAL AND ANTICANCER
LIPOPEPTIDES

Attorney Docket No.: 85189-16300

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 C.F.R. § 1.323

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

It is requested that a Certificate of Correction be issued in connection with the above-identified patent correcting the errors listed on the accompanying Form PTO-1050. The corrections requested are as follows.

On the Title page, Item (57) **ABSTRACT**, line 2, change "acid The" to -- acid. The --.

This request is being made pursuant to 37 C.F.R. § 1.323 to correct errors of a clerical or typographical nature and do not involve changes that would constitute new matter or require reexamination. A fee of \$100 is believed to be due for this request. Please charge the required fees to Winston & Strawn LLP Deposit Account No. 50-1814. Please issue a Certificate of Correction in due course.

Respectfully submitted,

Date: June 17, 2010



Allan A. Fanucci, Reg. No. 30,256

WINSTON & STRAWN LLP
Customer No. 28765
212-294-3311

**UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION**

PATENT NO. : 7,671,011 B2

Page 1 of 1

APPLICATION NO. : 10/560,727

DATED: : March 2, 2010

INVENTOR(S) : Shai et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title Page:

Item (57) ABSTRACT, line 2, change "acid The" to -- acid. The --.



US007671011B2

(12) **United States Patent**
Shai et al.(10) **Patent No.: US 7,671,011 B2**
(45) **Date of Patent: Mar. 2, 2010**(54) **ANTIMICROBIAL AND ANTICANCER
LIPOPEPTIDES**(75) Inventors: **Yechiel Shai, Yehud (IL); Dorit
Avrahami, Ashdod (IL)**(73) Assignee: **Yeda Research & Development Co.
Ltd., Rehovot (IL)**(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 327 days.(21) Appl. No.: **10/560,727**(22) PCT Filed: **Jun. 18, 2004**(86) PCT No.: **PCT/IL2004/000544**§ 371 (c)(1),
(2), (4) Date: **Oct. 10, 2006**(87) PCT Pub. No.: **WO2004/110341**PCT Pub. Date: **Dec. 23, 2004**(65) **Prior Publication Data**

US 2007/0072808 A1 Mar. 29, 2007

Related U.S. Application Data(60) Provisional application No. 60/479,465, filed on Jun.
19, 2003.(51) **Int. Cl.**
C07K 7/00 (2006.01)(52) **U.S. Cl.** 514/2; 530/327; 530/328(58) **Field of Classification Search** 514/2;
530/329, 330, 331, 327, 328
See application file for complete search history.(56) **References Cited****U.S. PATENT DOCUMENTS**

3,817,973 A *	6/1974	Bouchaudon et al.	530/319
5,583,198 A	12/1996	Whittaker	530/345
5,837,249 A	11/1998	Heber-Katz et al.	424/186.1
5,871,746 A	2/1999	Boutillon et al.	424/208.1
6,011,008 A	1/2000	Domb et al.	514/8
6,011,013 A	1/2000	Carr et al.	514/13
6,172,038 B1	1/2001	Shai et al.	514/2
6,183,736 B1	2/2001	Moyne et al.	424/93.462
6,384,013 B1	5/2002	Burkhardt et al.	514/11
6,794,490 B2 *	9/2004	Hill et al.	530/317
7,262,268 B2 *	8/2007	Morytko et al.	530/317
2002/0077317 A1	6/2002	Das	514/171

FOREIGN PATENT DOCUMENTS

WO	WO98/37090	8/1998
WO	WO02/40529	5/2002

OTHER PUBLICATIONS

Creemer L. C. (J Med Chem. 39(25), 5021-4, 1996).*

Uehara Y (Journal of Antibiotics 29(9), 937-943, 1976).*

Schott H (Anti-Cancer Drug Design 11(6), 451-62, 1996).*

Trani A [Farmaco (Societa Chimica Italiana: 1989), 51(7), 503-512,
1996].*

Clark C. R. (J Med Chem. 30(7), 1214-18, 1987).*

Alexander et al., "Antifungal resistance trends towards the year 2000.
Implications for therapy and new approaches". Drugs. Nov.
1997;54(5):657-78.Avrahami et al., "Effect of multiple aliphatic amino acids substitu-
tions on the structure, function, and mode of action of diastereomeric
membrane active peptides". Biochemistry Oct. 23,
2001;40(42):12591-603.Avrahami et al., "Conjugation of a magainin analogue with lipophilic
acids controls hydrophobicity, solution assembly, and cell selectiv-
ity". Biochemistry Feb. 19, 2002; 41(7):2254-63.Bechinger, "The structure, dynamics and orientation of antimicrobial
peptides in membranes by multidimensional solid-state NMR spec-
troscopy". Biochim Biophys Acta. Dec. 15, 1999;1462(1-2):157-83.Denning DW. "Epidemiology and pathogenesis of systemic fungal
infections in the immunocompromised host". J Antimicrob
Chemother. Oct. 1999;28 Suppl B:1-16.Efron et al., "Direct interaction of dermaseptin S4 aminoheptanoyl
derivative with intraerythrocytic malaria parasite leading to increased
specific antiparasitic activity in culture". J Biol Chem. Jul. 5,
2002;277(27):24067-72. Epub Apr. 5, 2002.Gavish et al., "Growth inhibition of prostate cancer xenografts by
halofuginone". Prostate. May 1, 2002;51(2):73-83.Groll et al., "Trends in the postmortem epidemiology of invasive
fungal infections at a university hospital". J Infect. Jul.
1996;33(1):23-32.Hong et al., "Structure and organization of hemolytic and
nonhemolytic diastereomers of antimicrobial peptides in mem-
branes". Biochemistry. Dec. 21, 1999;38(51):16963-73.Merrifield, "Solid phase peptide synthesis". J. Am. Chem. Soc. Jan.
31, 1963; 85: 2149-2154.Minamoto et al., "Fungal infections in patients with acquired
immunodeficiency syndrome". Med Clin North Am. Mar.
1997;81(2):381-409.Oren et al., "Selective lysis of bacteria but not mammalian cells by
diastereomers of melittin: structure-function study". Biochemistry.
Feb. 18, 1997;36(7):1826-35.Oren et al., "A repertoire of novel antibacterial diastereomeric
peptides with selective cytolytic activity". J Biol Chem. Jun. 6,
1997;272(23):14643-9.Oren et al., "Mode of action of linear amphipathic alpha-helical
antimicrobial peptides". Biopolymers. 1998;47(6):451-63.Papo et al., "A novel lytic peptide composed of DL-amino acids
selectively kills cancer cells in culture and in mice". J Biol Chem.
Jun. 6, 2003;278(23):21018-23. Epub Mar. 19, 2003.

(Continued)

Primary Examiner—David Lukton(74) *Attorney, Agent, or Firm*—Winston & Strawn LLP(57) **ABSTRACT**

Lipophilic conjugates comprise a peptide coupled to a fatty
acid. The peptide comprises at least two positively charged
amino acid residues; the peptide after conjugation to the fatty
acid possessing antibacterial, antifungal, and/or anticancer
activity higher than prior to conjugation. The lipophilic con-
jugates are suitable for treatment of infections caused by
pathogenic organisms such as bacteria and fungi. The lipo-
philic conjugates are also suitable for sanitation, as disinfec-
tants, or for food preservation.

14 Claims, 4 Drawing Sheets